文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

冠脉与晚期肾病患者的侵入性或保守治疗后的健康状况

Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.
PubMed 文献 · N Engl J Med · 2020-03-30
一句话结论在稳定缺血性心脏病、中重度缺血及晚期慢性肾病患者中,初始侵入性策略相比保守策略在心绞痛相关健康状况方面未带来实质性或持续获益。

该研究为ISCHEMIA-CKD试验的次要分析,评估初始血管造影和血运重建加指南指导药物治疗(侵入性策略)与单纯指南指导药物治疗(保守策略)对心绞痛相关健康状况的影响。使用西雅图心绞痛问卷(SAQ)在随机化前及1.5、3、6个月及之后每6个月评估健康状况,主要终点为SAQ汇总评分(0-100分,分数越高表示心绞痛越少、功能和生活质量越好)。共705/777例参与者完成健康状况评估,49%在随机化前一个月内无心绞痛。3个月时侵入性策略组与保守策略组SAQ汇总评分估计平均差为2.1分(95%可信区间,-0.4至4.6),倾向于侵入性策略;基线每日或每周心绞痛者平均差最大(10.1分;95%可信区间,0.0至19.9),基线每月心绞痛者较小(2.2分;95%可信区间,-2.0至6.2),基线无心绞痛者几乎无差异(0.6分;95%可信区间,-1.9至3.3)。6个月时总体人群组间差异衰减(0.5分;95%可信区间,-2.2至3.4)。结论认为,在稳定缺血性心脏病、中重度缺血及晚期慢性肾病患者中,初始侵入性策略相比保守策略在心绞痛相关健康状况方面未带来实质性或持续获益。

要点

  • 在稳定缺血性心脏病、中重度缺血及晚期慢性肾病(eGFR<30 ml/min/1.73 m2或透析)患者中,初始侵入性策略相比保守策略在3个月时SAQ汇总评分平均差仅2.1分(95%可信区间,-0.4至4.6)。
  • 基线每日或每周心绞痛者3个月时SAQ汇总评分平均差为10.1分(95%可信区间,0.0至19.9),基线每月心绞痛者为2.2分(95%可信区间,-2.0至6.2),基线无心绞痛者为0.6分(95%可信区间,-1.9至3.3)。
  • 6个月时总体人群组间SAQ汇总评分差异衰减至0.5分(95%可信区间,-2.2至3.4)。
  • 49%的参与者在随机化前一个月内无心绞痛。
  • 该分析支持在晚期慢性肾病合并稳定缺血性心脏病患者中,初始侵入性策略未带来实质性或持续的心绞痛相关健康状况获益。

适用人群与场景

  • 稳定缺血性心脏病、中重度缺血及晚期慢性肾病患者(估计肾小球滤过率<30 ml/min/1.73 m2或接受透析)。

研究设计与关键结果

  • ISCHEMIA-CKD试验的次要分析,评估心绞痛相关健康状况;共705/777例参与者完成健康状况评估。
  • 主要终点为SAQ汇总评分(0-100分,分数越高表示心绞痛越少、功能和生活质量越好),在随机化前及1.5、3、6个月和之后每6个月评估。
  • 3个月时侵入性策略组与保守策略组SAQ汇总评分估计平均差为2.1分(95%可信区间,-0.4至4.6),倾向于侵入性策略。
  • 3个月时基线每日或每周心绞痛者平均差为10.1分(95%可信区间,0.0至19.9),基线每月心绞痛者为2.2分(95%可信区间,-2.0至6.2),基线无心绞痛者为0.6分(95%可信区间,-1.9至3.3)。
  • 6个月时总体人群组间差异衰减至0.5分(95%可信区间,-2.2至3.4)。
  • 49%的参与者在随机化前一个月内无心绞痛。

证据类型、等级与局限

  • 研究类型:ISCHEMIA-CKD试验的次要分析(随机对照试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在稳定缺血性心脏病、中重度缺血及晚期慢性肾病患者中,初始侵入性策略相比保守策略未带来实质性或持续的心绞痛相关健康状况获益;该结论不改变对此类患者初始侵入性策略不常规用于改善心绞痛相关健康状况的实践。

指南或共识出处

  • ISCHEMIA-CKD试验(ClinicalTrials.gov编号NCT01985360),由美国国家心肺血液研究所资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) as compared with guideline-based medical therapy alone (conservative strategy) in participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease (an estimated glomerular filtration rate of <30 ml per minute per 1.73 m2 or receipt of dialysis). A secondary objective of the trial was to assess angina-related health status.

METHODS: We assessed health status with the Seattle Angina Questionnaire (SAQ) before randomization and at 1.5, 3, and 6 months and every 6 months thereafter. The primary outcome of this analysis was the SAQ Summary score (ranging from 0 to 100, with higher scores indicating less frequent angina and better function and quality of life). Mixed-effects cumulative probability models within a Bayesian framework were used to estimate the treatment effect with the invasive strategy.

RESULTS: Health status was assessed in 705 of 777 participants. Nearly half the participants (49%) had had no angina during the month before randomization. At 3 months, the estimated mean difference between the invasive-strategy group and the conservative-strategy group in the SAQ Summary score was 2.1 points (95% credible interval, -0.4 to 4.6), a result that favored the invasive strategy. The mean difference in score at 3 months was largest among participants with daily or weekly angina at baseline (10.1 points; 95% credible interval, 0.0 to 19.9), smaller among those with monthly angina at baseline (2.2 points; 95% credible interval, -2.0 to 6.2), and nearly absent among those without angina at baseline (0.6 points; 95% credible interval, -1.9 to 3.3). By 6 months, the between-group difference in the overall trial population was attenuated (0.5 points; 95% credible interval, -2.2 to 3.4).

CONCLUSIONS: Participants with stable ischemic heart disease, moderate or severe ischemia, and advanced chronic kidney disease did not have substantial or sustained benefits with regard to angina-related health status with an initially invasive strategy as compared with a conservative strategy. (Funded by the National Heart, Lung, and Blood Institute; ISCHEMIA-CKD ClinicalTrials.gov number, NCT01985360.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Spertus JA, Jones PG, Maron DJ, et al. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. N Engl J Med. 2020. PMID: 32227754. doi:10.1056/NEJMoa1916374

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。